The chemohormonal therapy of metastatic melanoma: possible benefit of tamoxifen.

Abstract

Metastatic melanoma is difficult to treat because of low response rates to most chemotherapy regimens and short remission durations. Recently, a new chemohormonal regimen containing BCNU, cisplatin, DTIC and tamoxifen (BCDT) has been reported to be more promising. We have treated eight patients with this regimen and five patients responded, including three with complete responses (CR). One of these patients remains in CR beyond two years. Others have also reported response rates of 50% with this regimen with a few long-term remissions also. Two of our patients developed deep venous thromboses (DVT). The increased incidence of DVT with BCDT is attributed to the tamoxifen, which nevertheless appears to be a necessary component of this regimen. In two of our patients, short courses of tamoxifen were used and they both obtained responses (one CR, one PR) without DVT. The possibility of using short-course tamoxifen to reduce the incidence of DVT in this regimen, without impairing its efficacy, should be investigated.

• Authors: E B Crowell Jr, G M Higa
• Journal: The West Virginia medical journal (W V Med J) Vol. 89 Issue 6 Pg. 233-5 (Jun 1993) ISSN: 0043-3284 [Print] United States
• PMID: 8322461 (Publication Type: Journal Article)

Chemical References

• Tamoxifen
• Dacarbazine
• Cisplatin
• Carmustine

Topics

• Adult
• Aged
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Carmustine (administration & dosage)
• Cisplatin (administration & dosage)
• Dacarbazine (administration & dosage)
• Drug Administration Schedule
• Female
• Humans
• Male
• Melanoma (drug therapy, mortality, secondary)
• Middle Aged
• Tamoxifen (administration & dosage, adverse effects)
• Thrombophlebitis (chemically induced)